

1. Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM. Phase II study of sorafenib in patients with relapsed or refractory lymphoma. *Br J Haematol*. 2012 Jul;158(1):108-19.
2. Mariotti J, Spina F, Carniti C, Anselmi G, Lucini D, Vendramin A, Pregliasco F, Corradini P. Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies. *Eur J Haematol*. 2012 Aug;89(2):111-9.
3. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. *Blood*. 2012 Jul 5;120(1):9-19.
4. Barosi G, Merlini G, Billio A, Boccadoro M, Corradini P, Marchetti M, Massaia M, Tosi P, Palumbo A, Cavo M, Tura S. SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma. *Ann Hematol*. 2012 Jun;91(6):875-88.
5. Rambaldi A, Bacigalupo A, Fanin R, Ciceri F, Bonifazi F, Falda M, Lambertenghi-Deliliers G, Benedetti F, Bruno B, Corradini P, Alessandrino PE, Iacopino P, Arcese W, Scimè R, Raimondi R, Sica S, Castagna L, Lamparelli T, Oneto R, Lombardini L, Pollichieni S, Algarotti A, Carobbio A, Sacchi N, Bosi A. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. *Leukemia*. 2012 Aug;26(8):1779-85.
6. Corso A, Galli M, Mangiacavalli S, Rossini F, Nozza A, Pascutto C, Montefusco V, Baldini L, Cafro AM, Crippa C, Cazzola M, Corradini P. Response-adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progression-free survival in transplanted patients with multiple myeloma. *Am J Hematol*. 2011 Oct 14.
7. Zinzani PL, Corradini P, Gallamini A, Grossi A, Lazzarino M, Marchetti M, Martelli M, Rossi G, Vitolo U. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. *Leuk Lymphoma*. 2012 May;53(5):789-95.
8. Patriarca F, Einsele H, Spina F, Bruno B, Isola M, Nozzoli C, Nozza A, Sperotto A, Morabito F, Stuhler G, Festuccia M, Bosi A, Fanin R, Corradini P. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. *Biol Blood Marrow Transplant*. 2012 Apr;18(4):617-26.
9. Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, Ciceri F, Baronciani D, Scimè R, Pogliani E, Rambaldi A, Bonifazi F, Dalto S, Bruno B, Corradini P. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. *Leukemia*. 2012 Mar;26(3):520-6.
10. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood*. 2012 Jan 26;119(4):933-9; quiz 1093.

11. Björkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, Narni F, Musto P, Beksac M, Bosi A, Milone G, Corradini P, Goldschmidt H, de Witte T, Morris C, Niederwieser D, Gahrton G. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. *J Clin Oncol*. 2011 Aug 1;29(22):3016-22. Erratum in: *J Clin Oncol*. 2011 Sep 20;29(27):3721.
12. Barosi G, Bosi A, Abbracchio MP, Danesi R, Genazzani A, Corradini P, Pane F, Tura S. Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation. *Haematologica*. 2011 Jul;96(7):937-42.
13. Spina F, Montefusco V, Crippa C, Citro A, Sammassimo S, Olivero B, Gentili S, Galli M, Guglielmelli T, Rossi D, Falcone AP, Grasso M, Patriarca F, De Muro M, Corradini P. Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. *Leuk Lymphoma*. 2011 Jul;52(7):1262-70.
14. Spina F, Alessandrino PE, Milani R, Bonifazi F, Bernardi M, Luksch R, Fagioli F, Formica C, Farina L. Allogeneic stem cell transplantation in therapy-related acute myeloid leukemia and myelodysplastic syndromes: impact of patient characteristics and timing of transplant. *Leuk Lymphoma*. 2012 Jan;53(1):96-102.
15. Guglielmelli T, Bringhen S, Rrodhe S, Gay F, Cavallo F, Berruti A, Montefusco V, Piro E, Benevolo G, Petrucci MT, Caravita T, Offidani M, Corradini P, Boccadoro M, Saglio G, Palumbo A. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. *Eur J Cancer*. 2011 Apr;47(6):814-8.
16. Fracchiolla NS, Todoerti K, Bertazzi PA, Servida F, Corradini P, Carniti C, Colombi A, Cecilia Pesatori A, Neri A, Delilliers GL. Dioxin exposure of human CD34+ hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. *Toxicology*. 2011 Apr 28;283(1):18-23.
17. Thiel U, Wawer A, Wolf P, Badoglio M, Santucci A, Klingebiel T, Basu O, Borkhardt A, Laws HJ, Kodera Y, Yoshimi A, Peters C, Ladenstein R, Pession A, Prete A, Urban EC, Schwinger W, Bordigoni P, Salmon A, Diaz MA, Afanasyev B, Lisukov I, Morozova E, Toren A, Bielgorai B, Korsakas J, Fagioli F, Caselli D, Ehninger G, Gruhn B, Dirksen U, Abdel-Rahman F, Aglietta M, Mastrodicasa E, Torrent M, Corradini P, Demeocq F, Dini G, Dreger P, Eyrich M, Gozdzik J, Guilhot F, Holler E, Koscielniak E, Messina C, Nachbaur D, Sabbatini R, Oldani E, Ottinger H, Ozsahin H, Schots R, Siena S, Stein J, Sufliarska S, Unal A, Ussowicz M, Schneider P, Woessmann W, Jürgens H, Bregni M, Burdach S; Solid Tumor Working Party (STWP) and the Pediatric Disease Working Party (PDWP) of the European Group for Blood and Marrow Transplantation (EBMT); Asia Pacific Blood and Marrow Transplantation (APBMT); Pediatric Registry for Stem Cell Transplantations (PRST); MetaEICESS Study Group. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. *Ann Oncol*. 2011 Jul;22(7):1614-21.
18. Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A. Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. *J Clin Oncol*. 2011 Mar 1;29(7):814-24.

19. Corradini P, Sarina B, Farina L. Allogeneic transplantation for Hodgkin's lymphoma. *Br J Haematol.* 2011 Feb;152(3):261-72..
20. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. *Lancet.* 2010 Dec 18;376(9758):2075-85.
21. Corradini P, Farina L. Allogeneic transplantation for lymphoma: long-term outcome. *Curr Opin Hematol.* 2010 Nov;17(6):522-30.
22. Doderò A, Crocchiolo R, Patriarca F, Miceli R, Castagna L, Ciceri F, Bramanti S, Frungillo N, Milani R, Crippa F, Fallanca F, Englaro E, Corradini P. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. *Cancer.* 2010 Nov 1;116(21):5001-11.
23. Kyriakou C, Canals C, Sibon D, Cahn JY, Kazmi M, Arcese W, Kolbe K, Gorin NC, Thomson K, Milpied N, Niederwieser D, Indrák K, Corradini P, Sureda A, Schmitz N. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. *J Clin Oncol.* 2010 May 1;28(13):2227-32.
24. Sarina B, Castagna L, Farina L, Patriarca F, Benedetti F, Carella AM, Falda M, Guidi S, Ciceri F, Bonini A, Ferrari S, Malagola M, Morello E, Milone G, Bruno B, Mordini N, Viviani S, Levis A, Giordano L, Santoro A, Corradini P; Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. *Blood.* 2010 May 6;115(18):3671-7.
25. Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. *J Clin Oncol.* 2010 Feb 10;28(5):800-7.
26. Ruella M, Rocci A, Ricca I, Carniti C, Bodoni CL, Ladetto M, Caracciolo D, Boccadoro M, Carlo-Stella C, Corradini P, Tarella C. Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status. *Bone Marrow Transplant.* 2010 Mar;45(3):505-12.
27. Kröger N, Holler E, Kobbe G, Bornhäuser M, Schwerdtfeger R, Baurmann H, Nagler A, Bethge W, Stelljes M, Uharek L, Wandt H, Burchert A, Corradini P, Schubert J, Kaufmann M, Dreger P, Wulf GG, Einsele H, Zabelina T, Kvasnicka HM, Thiele J, Brand R, Zander AR, Niederwieser D, de Witte TM. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. *Blood.* 2009 Dec 17;114(26):5264-70.
28. Antinori S, Corbellino M, Necchi A, Corradini P, Vismara C, Montefusco V, Gianni AM. Immune reconstitution inflammatory syndrome associated with *Aspergillus terreus* pulmonary infection in an autologous stem cell transplant recipient. *Transpl Infect Dis.* 2010 Feb;12(1):64-8.

29. Vose JM, Ho AD, Coiffier B, Corradini P, Khouri I, Sureda A, Van Besien K, Dipersio J. Advances in mobilization for the optimization of autologous stem cell transplantation. *Leuk Lymphoma*. 2009 Sep;50(9):1412-21.
30. Crocchiolo R, Zino E, Vago L, Oneto R, Bruno B, Pollichieni S, Sacchi N, Sormani MP, Marcon J, Lamparelli T, Fanin R, Garbarino L, Miotti V, Bandini G, Bosi A, Ciceri F, Bacigalupo A, Fleischhauer K; Gruppo Italiano Trapianto di Midollo Osseo, Cellule Staminali Ematopoietiche (CSE) e Terapia Cellulare; Italian Bone Marrow Donor Registry. Nonpermissive HLA-DPB1 disparity is a significant independent risk factor for mortality after unrelated hematopoietic stem cell transplantation. *Blood*. 2009 Aug 13;114(7):1437-44.
31. Farina L, Carniti C, Dodero A, Vendramin A, Raganato A, Spina F, Patriarca F, Narni F, Benedetti F, Olivieri A, Corradini P. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation. *Haematologica*. 2009 May;94(5):654-62.
32. Kröger N, Badbaran A, Lioznov M, Schwarz S, Zeschke S, Hildebrand Y, Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. *Exp Hematol*. 2009 Jul;37(7):791-8.
33. Bregni M, Bernardi M, Servida P, Pescarollo A, Crocchiolo R, Treppiedi E, Corradini P, Ciceri F, Peccatori J. Long-term follow-up of metastatic renal cancer patients undergoing reduced-intensity allografting. *Bone Marrow Transplant*. 2009 Aug;44(4):237-42.
34. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR; International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. *Lancet Oncol*. 2009 Mar;10(3):223-32.
35. Dodero A, Carniti C, Raganato A, Vendramin A, Farina L, Spina F, Carlo-Stella C, Di Terlizzi S, Milanese M, Longoni P, Gandola L, Lombardo C, Corradini P. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. *Blood*. 2009 May 7;113(19):4771-9.
36. Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, Fanin R, Boccadoro M, Corradini P. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. *Leukemia*. 2009 Jun;23(6):1131-8.
37. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. *Blood*. 2009 Apr 2;113(14):3375-82.
38. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. *Leuk Lymphoma*. 2008 Nov;49(11):2156-62.
39. Patriarca F, Petrucci MT, Bringham S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palumbo A. Considerations in the

- treatment of multiple myeloma: a consensus statement from Italian experts. *Eur J Haematol.* 2009 Feb;82(2):93-105.
40. Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, van Lint MT, Iori AP, Santarone S, Porretto F, Pioltelli P, Visani G, Iacopino P, Fanin R, Bosi A; GITMO. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Haematologica.* 2008 Oct;93(10):1514-22.
 41. Stelljes M, van Biezen A, Slavin S, Olavarria E, Clark RE, Nagler A, Koza V, Kienast J, Niederwieser D, de Witte T, Ruutu T; complications subcommittee of the Chronic Leukemia Working Party. The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant.* 2008 Dec;42(11):739-42.
 42. Alessandrino EP, Della Porta MG, Bacigalupo A, Van Lint MT, Falda M, Onida F, Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marengo P, Pioltelli P, Malcovati L, Pascutto C, Oneto R, Fanin R, Bosi A; Gruppo Italiano Trapianto di Midollo Osseo (GITMO). WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). *Blood.* 2008 Aug 1;112(3):895-902.
 43. Tarella C, Zanni M, Magni M, Benedetti F, Patti C, Barbui T, Pileri A, Boccadoro M, Ciceri F, Gallamini A, Cortelazzo S, Majolino I, Mirto S, Corradini P, Passera R, Pizzolo G, Gianni AM, Rambaldi A. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innovative nei linfomi survey. *J Clin Oncol.* 2008 Jul 1;26(19):3166-75.
 44. Corradini P, Montefusco V. Does the addition of thalidomide to MP or low-intensity SCT improve survival in elderly multiple myeloma patients? *Nat Clin Pract Oncol.* 2008 May;5(5):254-5.
 45. Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. *Blood.* 2008 Apr 15;111(8):4004-13.
 46. Gahrton G, Iacobelli S, Bandini G, Björkstrand B, Corradini P, Crawley C, Hegenbart U, Morgan G, Kröger N, Schattenberg A, Schönland SO, Verdonck LF, Volin L, de Witte T, Niederwieser D; Myeloma Subcommittee of the EBMT. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. *Haematologica.* 2007 Nov;92(11):1513-8.
 47. Palumbo A, Falco P, Corradini P, Falcone A, Di Raimondo F, Giuliani N, Crippa C, Ciccone G, Omedè P, Ambrosini MT, Gay F, Brinchen S, Musto P, Foà R, Knight R, Zeldis JB, Boccadoro M, Petrucci MT; GIMEMA--Italian Multiple Myeloma Network. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. *J Clin Oncol.* 2007 Oct 1;25(28):4459-65.
 48. Corradini P, Carrabba MG, Farina L. Molecular methods used for the detection of autologous graft contamination in lymphoid disorders. *Methods Mol Med.* 2007;134:179-96.
 49. Corradini P, Doderò A, Farina L, Fanin R, Patriarca F, Miceli R, Matteucci P, Bregni M, Scimè R, Narni F, Pogliani E, Locasciulli A, Milani R, Carniti C, Bacigalupo A, Rambaldi A,

- Bonifazi F, Olivieri A, Gianni AM, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. *Leukemia*. 2007 Nov;21(11):2316-23.
50. Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi. Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi). *Leukemia*. 2007 Aug;21(8):1802-11.
51. Farina L, Corradini P. Current role of allogeneic stem cell transplantation in follicular lymphoma. *Haematologica*. 2007 May;92(5):580-2.
52. Majolino I, Davoli M, Carnevalli E, Locasciulli A, Di Bartolomeo P, Scimè R, Corradini P, Sella C, Narni F, Musso M, Bregni M, Olivieri A, De Fabritiis P, Pogliani L, Arbelaez JE, Ruscio C, Bacigalupo A; GITO Institutions. Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. *Leuk Lymphoma*. 2007 Apr;48(4):759-66.
53. Carlo-Stella C, Guidetti A, Di Nicola M, Lavazza C, Cleris L, Sia D, Longoni P, Milanesi M, Magni M, Nagy Z, Corradini P, Carbone A, Formelli F, Gianni AM. IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3. *Cancer Res*. 2007 Apr 1;67(7):3269-75.
54. Giaccone L, Sorasio R, Patriarca F, Mattei D, Montefusco V, Peccatori J, Carnevale-Schianca F, Petrucci MT, Milone G, Guidi S, Rotta M, Fanin R, Corradini P, Boccadoro M, Bruno B. Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment. *Biol Blood Marrow Transplant*. 2007 Apr;13(4):497-9.
55. Secondino S, Carrabba MG, Pedrazzoli P, Castagna L, Spina F, Grosso F, Bertuzzi A, Bay JO, Siena S, Corradini P, Niederwieser D, Demirel T; European Group for Blood and Marrow Transplantation Solid Tumors Working Party. Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation. *Haematologica*. 2007 Mar;92(3):418-20.
56. Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scimè R, Console G, Milone G, Marotta G, Dominiello A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M; Gruppo Italiano Trapianto Midollo Osseo. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. *Eur J Haematol*. 2007 Apr;78(4):330-7.
57. Ciceri F, Bonini C, Markt S, Zappone E, Servida P, Bernardi M, Pescarollo A, Bondanza A, Peccatori J, Rossini S, Magnani Z, Salomoni M, Benati C, Ponzoni M, Callegaro L, Corradini P, Bregni M, Traversari C, Bordignon C. Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. *Blood*. 2007 Jun 1;109(11):4698-707.
58. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J, Wiktor-Jedrzejczak W, Niederwieser D, Hallek M, Montserrat E; Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. *Leukemia*. 2007 Jan;21(1):12-7.

59. Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C. Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial. *Leukemia*. 2006 Oct;20(10):1840-7.
60. Corradini P, Tarella C, Zallio F, Doderò A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. *Leukemia*. 2006 Sep;20(9):1533-8.
61. Bruno B, Patriarca F, Sorasio R, Mattei D, Montefusco V, Peccatori J, Bonifazi F, Petrucci MT, Milone G, Guidi S, Giaccone L, Rotta M, Fanin R, Boccadoro M, Corradini P; Gruppo Italiano Trapianti di Midollo. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. *Haematologica*. 2006 Jun;91(6):837-9.
62. van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma. *Bone Marrow Transplant*. 2006 Jun;37(12):1135-41.
63. Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milanese M, Milani R, Carrabba M, Farina L, Formelli F, Gianni AM, Corradini P. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice. *Exp Hematol*. 2006 Jun;34(6):721-7. 69: Corradini P, Auriemma F, De Rosa C. Crystals and crystallinity in polymeric materials. *Acc Chem Res*. 2006 May;39(5):314-23.
64. van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma. *Blood*. 2006 Apr 15;107(8):3415-6.
65. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, Carreras E, Devergie A, Guglielmi C, Kolb HJ, Niederwieser D; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). *Haematologica*. 2006 Apr;91(4):513-21.
66. Bregni M, Fleischhauer K, Bernardi M, Pescarollo A, Guggiari E, Lunghi F, Deola S, Scaramuzza S, Re F, Setola E, Monari M, Mazzi B, Servida P, Corradini P, Peccatori J. Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer. *Bone Marrow Transplant*. 2006 Feb;37(3):311-5.
67. Poloni A, Leoni P, Buscemi L, Balducci F, Pasquini R, Masia MC, Viola N, Costantino E, Discepoli G, Corradini P, Tagliabracci A, Olivieri A. Engraftment capacity of mesenchymal cells following hematopoietic stem cell transplantation in patients receiving reduced-intensity conditioning regimen. *Leukemia*. 2006 Feb;20(2):329-35.

68. Gahrton G, Iacobelli S, Björkstrand B, Bourhis J, Corradini P, Crawley C, Morris C, Niederwieser D; European Group for Blood and Marrow Transplantation. Role of stem cell transplantation in myeloma. *Hematology*. 2005;10 Suppl 1:127-8.
69. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, Zambelli A, Da Prada GA, Pedrazzoli P, Siena S, Massenkeil G, Martino R, Lenhoff S, Corradini P, Rosti G, Ringden O, Bregni M, Niederwieser D; European Bone Marrow Transplantation Solid Tumor Working Party. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. *Cancer*. 2005 Nov 15;104(10):2099-103.
70. Corradini P, Zallio F, Mariotti J, Farina L, Bregni M, Valagussa P, Ciceri F, Bacigalupo A, Doderò A, Lucesole M, Patriarca F, Rambaldi A, Scimè R, Locasciulli A, Bandini G, Gianni AM, Tarella C, Olivieri A. Effect of age and previous autologous transplantation on nonrelapse mortality and survival in patients treated with reduced-intensity conditioning and allografting for advanced hematologic malignancies. *J Clin Oncol*. 2005 Sep 20;23(27):6690-8.
71. Doderò A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V, Farina L, Milanese M, Longoni P, Carlo-Stella C, Corradini P. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed. *Exp Hematol*. 2005 Aug;33(8):920-7.
72. Vacca A, Scavelli C, Montefusco V, Di Pietro G, Neri A, Mattioli M, Bicciato S, Nico B, Ribatti D, Dammacco F, Corradini P. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma. *J Clin Oncol*. 2005 Aug 10;23(23):5334-46.
73. Corradini P, Farina L. Immune-mediated attack in relapsed Hodgkin's lymphoma. *Lancet*. 2005 Jun 4-10;365(9475):1906-8.
74. Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G, Martino R, Russell N, van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. *Leukemia*. 2005 Jun;19(6):1029-33.
75. Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kröger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. *Bone Marrow Transplant*. 2005 Mar;35(6):609-17.
76. Ruutu T, Corradini P, Gratwohl A, Holler E, Apperley J, Dini G, Rocha V, Schmitz N, Socié G, Niederwieser D. Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplant*. 2005 Jan;35(2):121-4.
77. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, Ciceri F, Milone G, Cesaro S, Bandini G, Dini G, Corradini P, Fanin R. Infliximab treatment for steroid-refractory acute graft-versus-host disease. *Haematologica*. 2004 Nov;89(11):1352-9.
78. Barosi G, Boccadoro M, Cavo M, Corradini P, Marchetti M, Massaia M, Merlini G, Tosi P, Tura S; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation. Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of

- Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). *Haematologica*. 2004 Jun;89(6):717-41.
79. Corradini P, Doderò A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. *J Clin Oncol*. 2004 Jun 1;22(11):2172-6.
 80. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S, Cuttica A, Rosato R, Farina L, Boccadoro M, Benedetti F, Pileri A, Tarella C. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. *J Clin Oncol*. 2004 Apr 15;22(8):1460-8.
 81. Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanesi M, Longoni P, Matteucci P, Formelli F, Ravagnani F, Corradini P, Gianni AM. Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers. *Blood*. 2004 May 1;103(9):3287-95.
 82. Voena C, Malnati M, Majolino I, Fagà G, Montefusco V, Farina L, Santoro A, Ladetto M, Boccadoro M, Corradini P. Detection of minimal residual disease by real-time PCR can be used as a surrogate marker to evaluate the graft-versus-myeloma effect after allogeneic stem cell transplantation. *Bone Marrow Transplant*. 2003 Oct;32(8):791-3.
 83. Ladetto M, Mantoan B, Ricca I, Astolfi M, Drandi D, Compagno M, Vallet S, dell'Aquila M, Alfano A, Rossatto P, Rocci A, Vitolo U, Corradini P, Boccadoro M, Tarella C. Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone. *Exp Hematol*. 2003 Sep;31(9):784-8.
 84. Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, Van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. *Leukemia*. 2003 May;17(5):841-8. Review.
 85. Martino R, Giralt S, Caballero MD, Mackinnon S, Corradini P, Fernández-Avilés F, San Miguel J, Sierra J. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study. *Haematologica*. 2003 May;88(5):555-60.
 86. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. *Blood*. 2003 Sep 1;102(5):1927-9.
 87. Majolino I, Corradini P, Scimè R, Falda M, Bosi A, Tarella C, Musso M, Olivieri A, Boccadoro M, Marcenò R, Santoro A, Pileri A. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. *Bone Marrow Transplant*. 2003 May;31(9):767-73.
 88. Ladetto M, Drandi D, Compagno M, Astolfi M, Volpato F, Voena C, Novarino A, Pollio B, Addeo A, Ricca I, Falco P, Cavallo F, Vallet S, Corradini P, Pileri A, Tamponi G, Palumbo A, Bertetto O, Boccadoro M, Tarella C. PCR-detectable nonneoplastic Bcl-2/IgH

- rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy. *J Clin Oncol.* 2003 Apr 1;21(7):1398-403.
89. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S, Rambaldi A, Cortelazzo S, Patti C, Parvis G, Benedetti F, Capria S, Corradini P, Tarella C, Barbui T. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). *Blood.* 2003 Jul 15;102(2):749-55.
 90. Dodero A, Perfetti V, Ciceri F, Corradini P. Clinical and molecular remission following reduced intensity conditioning and allogeneic transplantation in a patient with refractory multiple myeloma. *Haematologica.* 2002 Dec;87(12):ECR41.
 91. Ladetto M, Corradini P, Vallet S, Benedetti F, Vitolo U, Martelli M, Brugiattelli M, Coser P, Perrotti A, Majolino I, Fioritoni G, Morandi S, Musso M, Zambello R, Chisesi T, Di Renzo N, Vivaldi P, De Crescenzo A, Gallamini A, Salvi F, Santini G, Boccomini C, Sorio M, Astolfi M, Drandi D, Pileri A, Tarella C. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). *Blood.* 2002 Sep 1;100(5):1559-65.
 92. Voena C, Locatelli G, Castellino C, Omedè P, Ladetto M, Zappone E, Milani R, Perfetti V, Boccadoro M, Pileri A, Lusso P, Villa C, Malnati M, Corradini P. Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system. *Br J Haematol.* 2002 Jun;117(3):642-5.
 93. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I, Voena C, Zaniboni A, Bordignon C, Corradini P. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. *Blood.* 2002 Jun 1;99(11):4234-6.
 94. Corradini P, Voena C, Astolfi M, Delloro S, Pilotti S, Arrigoni G, Bregni M, Pileri A, Gianni AM. Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. *Ann Oncol.* 2001 Dec;12(12):1693-8.
 95. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeve MR, Tresoldi M, Pileri A, Bordignon C, Bregni M. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. *Blood.* 2002 Jan 1;99(1):75-82.